Hypoglycemia: When used in combination with other medications for diabetes, such as insulin or sulfonylureas, Semaglutide can increase the risk of hypoglycemia (low blood sugar)
Pregnant or breastfeeding women should consult their healthcare provider before use, as safety in these groups has not been established
ClinicalTrials.gov number, NCT04881760.) Phase 2 Trial of Retatrutide for Obesity In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in substantial reductions in body weight.
Ignoring these conditions can lead to serious complications
If you receive Extra Help, ask your doctor and pharmacist whether the $50 monthly copay is manageable given your income